Allergan Adds Two Experts to Eye Care Division

Allergan has announced two new additions to leadership roles in Allergan Eye Care.

E. Randy Craven, MD, FACS, has joined Allergan Eye Care as medical director of the U.S. medical affairs glaucoma organization. A pioneer of minimally-invasive glaucoma surgery, Dr. Craven previously served as chief, Wilmer Eye Institute–Bethesda, and associate professor of ophthalmology, Johns Hopkins University.

“Throughout my experience diagnosing and treating patients with significant glaucoma and advanced anterior segment disease, I have always been deeply involved in clinical research to advance the science and efficacy of glaucoma therapies,” Dr. Craven said. “From my perspective, Allergan has always been a leader in developing new minimally-invasive glaucoma surgeries and glaucoma drug delivery platforms, so I’m looking forward to being part of that effort to reach more patients and preserve their vision.”

Allergan also announced that Scott Schachter, OD, FBCLA, will serve as scientific director of presbyopia and ocular surface disease. Dr. Schachter joins Allergan from the private practice he founded in Pismo Beach, California. He is also an adjunct clinical professor at Southern California College of Optometry and a global ambassador for the Tear Film & Ocular Surface Society.

“In a clinical practice focused on ocular surface disease, I understand Allergan’s industry-leading role in helping eye care professionals manage conditions like dry eye disease,” Dr. Schachter says. “I’m excited to be part of the process of bringing forth therapies for dry eye, as well as groundbreaking treatments for presbyopia—two conditions that, combined, impact most patients in an optometry practice.”